DXCM Insider Trading

Insider Ownership Percentage: 0.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $9,243,946.62

DexCom Insider Trading History Chart

This chart shows the insider buying and selling history at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

DexCom Share Price & Price History

Current Price: $66.14
Price Change: Price Decrease of -1.16 (-1.72%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for DXCM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$66.14Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for DexCom (NASDAQ:DXCM)

97.75% of DexCom stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DXCM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$41Mbought$13MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4B-$2B$0$2B$4BTotal InflowsTotal Outflows
DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More on DexCom

Today's Range

Now: $66.14
Low: $64.99
High: $67.66

50 Day Range

MA: $76.92
Low: $59.83
High: $90.75

52 Week Range

Now: $66.14
Low: $57.52
High: $139.24

Volume

4,787,867 shs

Average Volume

4,188,339 shs

Market Capitalization

$25.93 billion

P/E Ratio

46.25

Dividend Yield

N/A

Beta

1.5

Who are the company insiders with the largest holdings of DexCom?

DexCom's top insider investors include:
  1. Kevin R Sayer (CEO)
  2. Jacob Steven Leach (COO)
  3. Jacob Steven Leach (EVP)
  4. Steven Robert Pacelli (Director)
  5. Jereme M Sylvain (EVP)
  6. Michael Jon Brown (EVP)
  7. Jereme M Sylvain (CFO)
  8. Sadie Stern (EVP)
  9. Barry J Regan (EVP)
  10. Steven R Altman (Director)
  11. Shelly Ramasamy Selvaraj (SVP)
  12. Paul R Flynn (EVP)
  13. Matthew Vincent Dolan (EVP)
  14. Matthew Vincent Dolan (SVP)
  15. Bridgette P Heller (Director)
Learn More about top insider investors at DexCom.

Who are the major institutional investors of DexCom?

DexCom's top institutional investors include:
  1. Congress Asset Management Co. — 0.30%
  2. Rhumbline Advisers — 0.21%
  3. GAMMA Investing LLC — 0.13%
  4. Gradient Investments LLC — 0.07%
  5. Czech National Bank — 0.02%
  6. Woodstock Corp — 0.01%
Learn More about top institutional investors of DexCom stock.

Which major investors are selling DexCom stock?

During the previous quarter, DXCM stock was sold by these institutional investors:
  1. Congress Asset Management Co.
  2. E. Ohman J or Asset Management AB
  3. Sentry Investment Management LLC
  4. Parallel Advisors LLC
In the previous year, company insiders that have sold DexCom company stock include:
  1. Kevin R Sayer (CEO)
  2. Jacob Steven Leach (COO)
  3. Jacob Steven Leach (EVP)
  4. Steven Robert Pacelli (Director)
  5. Jereme M Sylvain (EVP)
  6. Michael Jon Brown (EVP)
  7. Jereme M Sylvain (CFO)
  8. Sadie Stern (EVP)
Learn More investors selling DexCom stock.

Which major investors are buying DexCom stock?

In the last quarter, DXCM stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
  2. Fulcrum Capital LLC
  3. Rhumbline Advisers
  4. Gradient Investments LLC
  5. Sendero Wealth Management LLC
  6. Central Pacific Bank Trust Division
  7. Czech National Bank
  8. Portside Wealth Group LLC